Latest Conference Articles

October 16th 2017, 10:32pm

IASLC World Conference on Lung Cancer

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the results of the ALTA trial, which is exploring brigatinib (Alunbrig) in patients with ALK-positive non-small cell lung cancer.

October 16th 2017, 9:24pm

IASLC World Conference on Lung Cancer

A lower dose of ceritinib taken with a low-fat meal showed similar efficacy with fewer dose reductions and less severe gastrointestinal adverse events versus a 750-mg dose taken without food for patients with untreated ALK-positive metastatic non­–small cell lung cancer.

October 16th 2017, 8:54pm

IASLC World Conference on Lung Cancer

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) induced an objective response rate of 46% in patients with recurrent small cell lung cancer with high tumor mutation burden, according to an exploratory analysis from the phase I/II CheckMate-032 study.

October 16th 2017, 6:04am

IASLC World Conference on Lung Cancer

In addition to proving the superiority of alectinib versus crizotinib, the phase III ALEX trial provided clear guidance on which of 2 assays evaluated could provide stronger guidance on which patients would respond to ALK-specific therapy.

October 14th 2017, 9:41pm

IASLC World Conference on Lung Cancer

Fred R. Hirsch, MD, PhD, provides highlights of the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer, leading with his excitement for updated quality-of-life data from the PACIFIC trial of patients with locally advanced, unresectable stage III non–small cell lung cancer.

October 11th 2017, 2:51am

NCCN Hematologic Malignancies Congress

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease in acute myeloid leukemia.

October 11th 2017, 2:50am

NCCN Hematologic Malignancies Congress

Sandy Wong, MD, assistant professor, Division of Hematology/Oncology, UCSF School of Medicine, discusses monoclonal antibodies in plasma cell neoplasms.

October 11th 2017, 12:54am

NCCN Hematologic Malignancies Congress

The National Comprehensive Cancer Network guidelines for the management of polycythemia vera and essential thrombocythemia have been updated to create a more uniform system of management for healthcare providers to follow in clinical practice.

October 10th 2017, 2:19am

Global Congress on Bladder Cancer

The therapeutic landscape is rapidly being altered by clinical trials of immunotherapy for patients with metastatic urothelial carcinoma, but simply changing the way quality of life is monitored could provide dramatic improvements in overall survival.

October 10th 2017, 1:11am

Global Congress on Bladder Cancer

The aim of treating NMIBC is avoid the loss of the bladder and to prevent recurrence and progression to muscle-invasive disease.

October 9th 2017, 11:34pm

NCCN Hematologic Malignancies Congress

Defined composition CAR T cells directed against CD19 have potent anti-tumor activity in B cell malignancies, including acute lymphocytic leukemia.

October 9th 2017, 7:04am

NCCN Hematologic Malignancies Congress

After nearly 40 years with little in the way of drug development for the treatment of acute myeloid leukemia, four new drugs have been approved by the FDA in 2017 for AML, and several promising agents are in development.

October 8th 2017, 11:54pm

NCCN Hematologic Malignancies Congress

The treatment approach for patients with relapsed/refractory multiple myeloma should be tailored based on biology of the disease, frailty of the patient, and comorbidities.

October 8th 2017, 10:55pm

NCCN Hematologic Malignancies Congress

Shaji K. Kumar, MD, discusses proper diagnosis, risk stratification, and personalized medicine for patients with newly-diagnosed multiple myeloma.

October 8th 2017, 9:10pm

NCCN Hematologic Malignancies Congress

Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.

October 8th 2017, 9:04pm

NCCN Hematologic Malignancies Congress

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses response in follicular lymphoma.

October 8th 2017, 5:31am

NCCN Hematologic Malignancies Congress

In relapsed classical Hodgkin lymphoma, the era of therapies post-brentuximab vedotin is developing rapidly.

October 8th 2017, 3:33am

NCCN Hematologic Malignancies Congress

William G. Wierda, MD, PhD, discusses the continued importance of ibrutinib, the promise for novel combinations, and the impact this progress has had on sequencing for CLL.

October 8th 2017, 12:41am

NCCN Hematologic Malignancies Congress

Survival for patients with grade 1 to 2 follicular lymphoma is now measured in decades to coincide with improvements in therapy.

October 7th 2017, 11:46pm

NCCN Hematologic Malignancies Congress

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the management of newly diagnosed patients with multiple myeloma.